Press release
NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE
Real World Evidence Study Showed use of Prolia Reduced Fracture Risk in Postmenopausal Women With Osteoporosis Versus Alendronate Treatment Longer Duration of
About this update from Amgen Inc.
[{"type":"text","content":"Real World Evidence Study Showed use of Prolia Reduced Fracture Risk in Postmenopausal Women With Osteoporosis Versus Alendronate Treatment\nLonger Duration of Treatment With Prolia Was Associated With Greater Improvements in Fracture Risk Reduction\nData is From Real-World Study with Nearly Half a Million Patients Comparing Prolia to Alendronate\nTHOUSAND OAKS, Calif., May 8, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia® (denosumab) injection reduced fracture risk in patients versus oral alendronate, a frequently prescribed bisphosphonate treatment. Treatment with Prolia was also associated with greater reductions in fracture risk over time. The data were presented during an oral presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO), in Barcelona, May 4-7, 2023.\nTo view the Multimedia News Release, please visit: https://www.multivu.com/players/English/9094351-new-data-amgen-prolia-denosumab/\n\"Amgen has long been committed to reducing the impact of osteoporosis, an underdiagnosed and undertreated disease that increases the risk for bone loss and fracture for millions of post-menopausal women,\" said Jyothis George, vice president and global medical therapeutic area head, General Medicine, at Amgen. \"May is Osteoporosis Awareness and Prevention Month, making this a great time to share these new data about Prolia and the important role it can play in reducing the risk of potentially life-altering fractures in these women at high risk for fracture.\" \nThe retrospective, observational study assessed U.S. Medicare beneficiary data on 478,651 postmenopausal women aged 66 or older with no history of prior osteoporosis treatment who initiated Prolia (n=89,115) or oral alendronate (n=389,536) treatment between Jan. 1, 2012 and Dec. 31, 2018. The study's results showed that Prolia reduced the relative risk of fracture across various fracture types. At the end of follow-up, the overall relative risks were:\nA 36% reduced risk of hip fractures (RR=0.64; 95% CI: 0.39-0.90)A 43% reduced risk of nonvertebral fractures, including fractures to the hip, humerus, pelvis, radus/ulna and other femur (RR=0.57; 95% CI: 0.42-0.71)A 30% r...